

國立臺灣大學公共衛生學院環境與職業健康科學研究所



碩士論文

Institute of Environmental and Occupational Health Sciences

College of Public Health

National Taiwan University

Master Thesis

慢性暴露大氣細懸浮微粒後大鼠不同器官與血清
的脂質變化

Lipid Changes in Different Organs and Serum of Rats after
Chronic Exposure to Ambient Fine Particulate Matter

陳婷甄

Ting-Zhen Chen

指導教授：林靖愉 博士

共同指導教授：鄭尊仁 博士

Advisor: Ching-Yu Lin, PhD

Co-Advisor: Tsun-Jen Cheng, MD, ScD

中華民國 108 年 10 月

October, 2019

致謝

兩年多的碩士生涯，曾在過程中感到十分漫長，但轉眼地，也即將走到了終點。在林靖愉老師的研究室裡，學習著從未接觸過的領域，由於我沒有很多看 paper 經驗，也沒有什麼毒理學與分析化學的基礎，一開始感到很迷茫。還記得初期的 meeting 報告，每次報完我都覺得自己一團糟，連自己都無法認可自己，而且對於下一次的報告總是提心吊膽。後來隨著時間與經驗的累積，不知道何時開始，我慢慢可以在 seminar 上有良好的應答，甚至遠赴國際研討會張貼論文壁報，到最後此刻我可以完成一本自己的著作，這一路上要感謝非常多人的幫忙。

首先感謝我的指導教授—靖愉老師，在每一次我對自己的報告挫敗的時候，您總是給予我良好的建議，不加以責備，讓我在一次又一次的報告訓練中建立信心，還有您總是很鼓勵我們積極參與各樣的課程或研討會，告訴我們費用的部分老師可以支援，真的非常謝謝您。還有感謝尊仁老師，雖然老師總是說他沒辦法幫我什麼忙，但您把我視為鄭家研究室的一員，總是讓我參與鄭家的各式活動，讓我非常感激，還有鄭家的其他成員們，怡瑄、晨歡、琬儒與景州，謝謝你們都對我很好。還有感謝玟伶老師，除讓我有資料得以研究外，也謝謝老師在我疑問時給予解惑，是我的研究中很重要的一員。然後感謝嚴醫師，我從您那裡得到了非常良好的研究建議。感謝昇翰學長，學長就像親切的大哥哥，總是給予研究上的指引與鼓勵。皓然學長，靖愉老師家不可或缺的角色，每次 meeting 總是有學長給予的建議，讓大家都獲益良多。lab 的同儕們，包括怡儒學姊、尚廷學長、partner 書維與學弟泳宏，謝謝你們也都在我的研究所生涯中給予了大大小小的幫助。還有環衛所 R06 的大家，在研究生的路上一起同甘共苦，慶生、打 switch 等等都是很美好的回憶！

再來我要感謝爸媽，謝謝您們賺錢供我上學，生活無虞，總是叫我要吃好一点不要太省，除此之外，您們都給予我們這些小孩們很大的空間，信任我們可以對自己負責。當初知會你們要延畢的時候，我感受得到你們的失落，或許沒有參加到畢業典禮會是你們一輩子的遺憾，但我知道你們仍然以我為榮，我愛你們。

謝謝從小到大的朋友們，大學朋友佳妮、毓文、宜岑、佳穎、季穎、季桓、冠良、名毅、婕伶、喻宣、韻菀、嘉麒等，高中朋友沂鎂、晏伶、子甯、孟慈、靖涵、晨生、惠瑩、汶芳等，國中朋友彥霖、凱富、純甄、意茹、學宇、容德等。還有馨儀，謝你們都曾給予我陪伴，陪伴就是好的支持。

最後感謝皓文，研究所離家又更遠了，而研究所的生活不像大學一樣，在這裡很多事都必須獨自面對，一個人在台北的生活，謝謝你不管是在遠處還是在近處無時無刻的陪伴，是你吃掉我最多的淚水與抱怨，沒有你我根本不可能完成這個不可能的任務，所幸現在都撐過來了，謝謝你，也辛苦你了，你最棒！

陳婷甄 謹誌 2019.11.18

摘要




細懸浮微粒又稱 PM_{2.5}，它進入人體呼吸道後能在肺泡穿越氣血屏障，進而抵達血液循環系統然後傳遞至其他器官。過去文獻指出 PM_{2.5} 誘導的體內氧化壓力上升可能造成脂質的擾動，而含有磷酸膽鹼的脂質(phosphorylcholine-containing lipids)是人體構成細胞膜的最主要成分，在面對氧化攻擊時細胞膜是體內的第一道防線。本實驗室先前的研究使用脂質體學的方法探討在慢性暴露 PM_{2.5} 後大鼠肺部含有磷酸膽鹼脂質的變化，發現磷脂醯膽鹼(phosphatidylcholines, PCs)的顯著改變可能與肺部表面活性劑功能的損傷有關。然而除了肺臟外，PM_{2.5} 對人體其他器官的脂質效應目前仍不清楚。因此，在本研究中我們利用脂質體學的方法透過大鼠長期吸入 PM_{2.5} 的動物模型，去探討慢性暴露 PM_{2.5} 後不同器官與血液的脂質效應。

十隻六週大的雄性 SD 大鼠，五隻全身持續性地暴露於未經濃縮的含有 PM_{2.5} 的外來一般空氣，其他五隻則吸入通過懸浮微粒過濾器的空氣。整個實驗在臺北市臺大公衛大樓進行長達八個月，實驗結束後暴露組與控制組所測得的平均 PM_{2.5} 濃度分別為 $16.7 \pm 10.1 \mu\text{g}/\text{m}^3$ 與 $0.70 \pm 0.46 \mu\text{g}/\text{m}^3$ 。隨後採集動物的血液樣本及其各式器官，包括心臟、肝臟、胰臟、腎臟、脾臟、睪丸及副睪丸，接著將脂質從每個器官組織及血清中萃取出來進行極致液相層析串聯式質譜儀(UPLC-MS/MS)分析，得到的圖譜經過數據前處理後，再利用偏最小平方判別分析(partial least squares discriminant analysis)搭配無母數統計方法 Wilcoxon rank sum tests 去檢驗暴露組與控制組間的脂質變異。

本研究結果指出慢性暴露 PM_{2.5} 確實會在肺以外的器官造成脂質擾動的情形。偏最小平方判別分析顯示含磷酸膽鹼脂質在大鼠睪丸、胰臟、心臟、肝臟及腎臟的兩組別中有顯著差異，而無母數統計分析顯示在大鼠睪丸中發現最大量的含磷酸膽鹼脂質變化，包括多種磷脂醯膽鹼(lyso-PCs, diacyl-PCs, ether-linked PCs)及神經磷脂(sphingomyelins)，此改變推測可能與維持精子細胞膜完整性、抗氧化、抗發炎及輕微生精功能障礙有關。此外，在血液中的脂質調查發現與睪丸有一致的特定脂質 PC(16:0/18:1)下降趨勢，但其是否為 PM_{2.5} 毒性的潛在生物指標物需要更進一步的研究證實。總結，脂質體學是一種有效不偏頗且靈敏的方法去探究在 PM_{2.5} 造成嚴重損傷前體內的分子變化，同時幫助於潛在生物指標物的開發。

關鍵字：脂質體學、磷脂醯膽鹼、PM_{2.5}、慢性暴露、睪丸、毒性

Abstract



Fine particulate matter (PM_{2.5}) is able to pass the respiratory barrier and further enter the circulatory system, and consequently spread to the whole body. PM_{2.5}-induced toxicity has been correlated with oxidative stress, which may lead to lipid perturbation. Our previous studies have applied a lipidomic platform to investigate the chronic effects of PM_{2.5} exposure on the pulmonary lipids in rats inhaled ambient air, and found that significantly altered levels of phosphorylcholine-containing lipids, which might impair pulmonary surfactant functions. However, the effects of PM_{2.5} on phosphorylcholine-containing lipids in other organs have not been fully elucidated yet. In this study, we examined the lipid effects of chronic PM_{2.5} exposure on various organs and serum using a rat inhalation model.

Five male Sprague-Dawley rats were continually whole-body exposed to non-filtered and non-concentrated ambient air containing PM_{2.5} from the outside of the Public Health building in Taipei city for 8 months, while five rats were inhaled filtered air. The mean concentrations of PM_{2.5} in the exposure and control group were $16.7 \pm 10.1 \mu\text{g}/\text{m}^3$ and $0.70 \pm 0.46 \mu\text{g}/\text{m}^3$, respectively. Blood samples and various tissues, including heart, liver, kidney, pancreas, spleen, testis and epididymis were collected. Then lipids from each organ and serum were extracted for further ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) analysis. Subsequently, the partial least squares discriminant analysis (PLS-DA) and Wilcoxon rank sum tests were used to examine the variations of phosphorylcholine-containing lipids among samples.

Our results demonstrated that after the chronic and low-dose PM_{2.5} exposure, the lipidome were significantly different in the certain organs. In the PLS-DA models, the patterns of phosphorylcholine-containing lipids were altered in the testis, pancreas, heart, liver and kidney of rats exposed to PM_{2.5}. After statistical analyses, most of significantly changed phosphorylcholine-containing lipids were discovered in the rat testis after chronic PM_{2.5} exposure. The changed lipids include decreased lyso-phosphatidylcholines (PCs), increased unsaturated diacyl-PCs, a decreased ether-linked PC and increased sphingomyelins, which may be related to maintain membrane integrity of spermatozoa, play anti-oxidants and anti-inflammatory roles, and dysfunction of spermatogenesis. Additionally, our results showed decreased PC(16:0/18:1) was both observed in the serum

and testis. Further studies to verify potential biomarkers for PM_{2.5}-induced toxicity are needed. We concluded lipidomics is a powerful, unbiased, and sensitive approach to study biological molecular effects in different organs after long-term and low concentration PM_{2.5} exposure. Our study suggested target organs of PM_{2.5} exposure and revealed the underlying possible mechanisms of PM-induced toxicity and potential biomarkers.

Key words: Lipidomics, Phosphorylcholine-containing lipids, PM_{2.5}, Chronic exposure, Testis, Toxicity

Contents



致謝	i
摘要	ii
Abstract	iii
Contents	v
List of figures	vii
List of tables	viii
1. Introduction	1
1.1 Background	1
1.2 Fine particulate matter	1
1.3 Epidemiological studies on fine particulate matter	2
1.4 Mechanism of fine particulate matter-induced toxicity	3
1.5 Lipids and Lipidomics	4
1.6 Phosphorylcholine-containing lipids	5
1.7 Study objectives	8
2. Materials and methods	9
2.1 Experiment flow chart	9
2.2 Animal experiment	10
2.3 Lipid extraction	10
2.4 UPLC-MS/MS for phosphorylcholine-containing lipids profiling	11
2.5 Data preprocessing	12
2.6 Multivariate analysis	12
2.7 Univariate analysis	13
3. Results	15
3.1 PM _{2.5} exposure data	15
3.2 Phosphorylcholine-containing lipids composition in various organs of rat	15
3.3 Effects of PM _{2.5} on patterns of phosphorylcholine-containing lipids in the organs and serum of rats	16
3.4 Effects of PM _{2.5} on individual phosphorylcholine-containing lipids in the organs and serum of rats	18
3.4.1 Testis	18
3.4.2 Pancreas	19
3.4.3 Other organs	19

3.4.4 Serum	20
4. Discussion	21
4.1 Lipidome comparison among various organs of rat	21
4.2 Significantly changed phosphorylcholine-containing lipids in the rat testis after chronic PM _{2.5} treatment	22
4.3 Contrary trend of changes of phosphorylcholine-containing lipids in the rat pancreas after chronic PM _{2.5} treatment	26
4.4 Less changes of phosphorylcholine-containing lipids in the rat other organs of rats after chronic PM _{2.5} treatment	28
4.5 Lipid alterations in blood may reflect to organ toxicity	28
4.6 Limitation and future work	30
5. References	32

List of figures

Figure 1. Representative structures of various phosphorylcholine-containing lipids.	40
Figure 2. Phosphorylcholine-containing lipids composition in each organ of rat.	41
Figure 3. The PLS-DA score plot from the analysis of UPLC-MS/MS spectra of phosphorylcholine-containing lipids in each organ of rats after chronic ambient PM _{2.5} exposure.	42
Figure 4. Permutation test of PLS-DA model for phosphorylcholine-containing lipids in each organ of rats after chronic ambient PM _{2.5} exposure.	43

List of tables




Table 1. Significant changed phosphorylcholine-containing lipids in the testis of rats after chronic ambient PM _{2.5} exposure.	45
Table 2. Significant changed phosphorylcholine-containing lipids in the pancreas of rats after chronic ambient PM _{2.5} exposure.	47
Table 3. Significant changed phosphorylcholine-containing lipids in the heart, liver, and kidney of rats after chronic ambient PM _{2.5} exposure.	48
Table 4. Significant changed phosphorylcholine-containing lipids in the serum of rats after chronic ambient PM _{2.5} exposure.	49

1. Introduction




1.1 Background

In the last decades, with rapid development of industry and transportation, ambient air pollution has become a significant public health issue. Particulate matter (PM), metals, and gaseous pollutants etc. have associated with numerous adverse effects to humans [1, 2]. Especially, fine particulate matter (PM_{2.5}) gets more concern due to its complex composition and divergent mechanism of toxicity [3, 4]. Although several animal studies have focused on the acute effect of short-term PM exposure at high dose treatment by intratracheal instillation [5-7], the underlying knowledge on chronic inhalation of real world, non-concentrated ambient PM in animals remain unclear.

1.2 Fine particulate matter


PM_{2.5} refers to particulate matter with an aerodynamic diameter less than 2.5 μm . The main source of PM_{2.5} are the emissions from motor vehicles and the burning of coal [8], which cause the complex chemical properties of PM_{2.5}. The major components of PM_{2.5} are sulfates (SO₄²⁻), nitrates (NO₃⁻), ammonium (NH₄⁺) and metals. Characteristics of PM-induced toxicity have been related with particular size ranges and composition simultaneously [9]. The main route for the entry of the PM into the body is inhalation, comparing to ingestion and dermal contact [10]. Due to small sizes, PM_{2.5} is able to get deep into the respiratory bronchioles and alveoli where gas exchange occurs [11].



However, PM_{2.5} can not only affect the lung but also multiple extrapulmonary organs of the body. The possible pathways of PM_{2.5} leading to extrapulmonary effects of PM_{2.5} are speculated: (1) nano-sized particulate components can go through the respiratory barrier then into circulatory system and further distributed to whole body, (2) PM-induced lung injury produce bioactive components and cytokines that subsequently enter circulation and affect extrapulmonary tissues, (3) PM interacts with pulmonary nerves and activate the autonomic nervous system resulted in systemic alterations [12-14].

1.3 Epidemiological studies on fine particulate matter

Several epidemiological studies have shown the association between PM_{2.5} and numerous health effects, including increased hospital admissions, emergency room visits and mortality [15-17]. Moreover, typical pulmonary diseases have been reported, such as respiratory symptoms and lung cancer. However, more and more recent studies indicated that exposure to PM_{2.5} could induce the non-pulmonary disease [18]. For example, PM_{2.5} was related to adverse effects on male reproductive system [19]. Sperm morphology and motility chronologically negatively correlated with PM_{2.5} levels recorded in males in Salt Lake County after two to three months exposure [20]. Comparing to rural area, exposure to higher concentrations of SO₂ and NO₂ of urban ambient air may associate with worse semen quality in Chongqing urban males [21]. Some animal studies were also indicated relationship between PM_{2.5} and male reproductive dysfunction in rats [22, 23]. On the other hand, Pearson et al. suggested that ambient PM_{2.5} may cause the increased




prevalence of diabetes in the adult population in U.S. [24], and consistent results were found in animal model after PM_{2.5} exposure, which revealed inflammation of adipose tissue and insulin resistance [25]. American Heart Association (AHA) has indicated that from epidemiology to toxicological studies all provided powerful evidence about PM_{2.5} contributing to cardiovascular morbidity and mortality [26].

1.4 Mechanism of fine particulate matter-induced toxicity

Researchers have suggested several mechanisms about PM_{2.5} induced adverse health effects. After arriving at target cells, PM_{2.5} may alter the cellular physiological processes by increasing oxidative stress, inflammation, and genotoxicity, resulting in the injury on the tissues and organs, and finally develop to cardiopulmonary diseases, diabetes mellitus, adverse reproductive effects and others [4].

Oxidative stress has been considered as an important mechanism of PM_{2.5}-induced toxicities[27]. Oxidative stress occurs when the level of reactive oxygen species (ROS), a byproduct of energy metabolism pathway of aerobic organism, exceeds antioxidant capacity [28]. The environmentally persistent free radicals from the combustion-derived particles in PM_{2.5} via reduction-oxidation cycling, or PM_{2.5}-mediated activation of inflammatory cells, are both capable of generating excessive ROS [29, 30]. Afterward, these ROS can readily react molecules, such as lipids, proteins and DNA, altering their structure and function, and then cause damages to the target cells and tissues [31]. A number of studies have shown that lipid peroxidation are associated with increased levels



of PM_{2.5} [32-34]. When free radicals attack lipids that contain carbon-carbon double bonds, especially polyunsaturated fatty acids (PUFA) containing two or more double bonds, lipid peroxidation was occurred [34]. Lipids play important roles on maintaining the structure and function of cell membrane [35]. Cell culture studies showed PM_{2.5} may destroy the cell membrane integrity after the bright field microscopy analysis [36, 37]. Hence, a series of ROS induced by PM_{2.5} have the potential to induce a systemic oxidation of polyunsaturated phospholipids and severely impair membrane function.

As mentioned above, inflammation could prompt oxidant injury, thereby inflammation and oxidative stress are closely linked and inseparable [38]. Numerous studies have reported systemic inflammation was observed in humans and animals exposed to PM_{2.5}, with increased levels of inflammation biomarkers, including C-reactive protein (CRP), Interleukin-6 (IL-6), tumor necrosis factor α (TNF- α) and other markers [39-42]. Lysophospholipids and sphingolipids are bioactive lipids that could actively modulate the chronic inflammatory response and help the body to restore homeostatic balance [43]. In fact, previous studies indicated that not only certain lipid species act to regulate inflammatory responses, but inflammatory signaling also can influence lipid metabolism in biological process conversely [44].

1.5 Lipids and Lipidomics

Lipids are kind of hydrophobic small molecules, and their functions include cell membrane formation, energy storage, molecules regulating, and signaling [35]. Based on

their chemical structure and biosynthetic characteristics, lipids have been divided into eight categories by LIPID MAPS [45], including fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and polyketides.

Lipidomics is a branch of the field of metabolomics. Lipidomics aims to comprehensively identify and quantify a wide range of lipids, and determine lipid roles in physiological processes. Lipidomics can characterize the biochemical changes induced by environmental stimuli by detecting alterations of lipids [46]. Thousands of lipids can be detected at a time by high-performance mass spectrometry (MS), and presenting abundant information about qualitative and quantitative analysis simultaneously. Relying on the advance of MS analysis technology, lipidomic investigations on exploring disease biomarkers and illustrating metabolic pathways become more efficient and powerful [47]. Because of high sensitivity and high throughput properties, application of MS-based lipidomics is widely to numerous fields, such as toxicology, nutrition, environmental sciences, and others [48]. In the past, numerous PM studies using metabolomics showed the changes of lipids and importance of those lipid in response to PM exposure [49-51]. However, studies focusing on PM effects on lipids are little.

1.6 Phosphorylcholine-containing lipids

Phosphorylcholine-containing lipids are abundant membrane lipids, with significant biological importance. Phosphorylcholine-containing lipids include


phosphatidylcholines (PCs), a type of glycerophospholipids, and sphingomyelins (SMs), a type of sphingolipids, because their structures are both with a phosphocholine head group.



PCs are the major structural lipids in cell membranes and account for more than 50% of glycerophospholipids [52]. The basic composition of PCs is a glycerol backbone and a phosphocholine head group at the sn-3 position. Based on different fatty acyl substituents at the sn-1 and/or sn-2 position of glycerol backbone, PCs can be divided into lyso-phosphatidylcholines (lyso-PCs), diacyl-phosphatidylcholines (diacyl-PCs), plasmanylcholines (O-alkyl-acyl-PCs, O-PCs) and plasmenylcholines (O-alkenyl-acyl-PCs, P-PCs) (Figure 1). Moreover, the various numbers of carbons and double bonds on fatty acyl substituents also present different PCs, for instance, PC(16:0/18:1) means a fatty acyl substituents with 16 carbons and no double bond at the sn-1 position accompany with 18 carbons and 1 double bond at the sn-2 position.

SMs also play an important role in cell membrane and constitute 2–15% of the total phospholipid in mammal organs. Besides, certain part such as brain tissue and peripheral nervous tissue have even higher SM contents [53]. SM consists of a sphingosine backbone, a phosphocholine head group and fatty acids, which is one of the few membrane phospholipids not synthesized from glycerol. Overall, investigation of phosphorylcholine-containing lipids of various organs after chronic PM_{2.5} exposure may help to characterize the PM effects at molecular level and understand the potential health

effects.



Our laboratory has developed a liquid chromatography-tandem MS platform [54] to profile the alterations of phosphorylcholine-containing lipids in rat lungs after chronic PM_{2.5} exposure [55]. The results showed that PM exposure cause decreases in lyso-PCs, surfactant PCs, unsaturated PCs and plasmenylcholines which may indicate repeated inflammatory responses, injuries of alveolar cells, and altered membrane integrity. Additionally, emphysematous and inflammatory cells were observed on the lung of PM exposed rats [55]. Although the significantly altered phosphatidylcholine levels in the lung of rats, which may impair pulmonary surfactant functions, the lipid effects after chronic exposure of PM_{2.5} on other organs remain unclear.

1.7 Study objectives




The objectives of this study is as following:

- (1) To examine the effects of chronic $PM_{2.5}$ exposure on phosphorylcholine-containing lipids in various organs and blood through a rat inhalation model.
- (2) To clarify and compare $PM_{2.5}$ -induced lipid alteration in different organs, and suggest the target organs and potential biochemical mechanisms.
- (3) To determine whether the specific lipid alteration between the target organ and blood after chronic $PM_{2.5}$ exposure which can serve as potential biomarkers.

2. Materials and methods



2.1 Experiment flow chart



2.2 Animal experiment




All the procedures of animal experiments were conducted by Dr. Tsun-Jen Cheng's laboratory [55, 56]. The animal care and experiments were approved by the National Taiwan University Institutional Animal Care and the Use Committee. Briefly, ten male Sprague-Dawley rats aged six weeks were purchased from Lasco, Charles River Technology (Yilan, Taiwan). The rats had acclimatized in cages with enough food and water for 14 days before the experiment was conducted. Exposure group (n=5) were continually whole-body exposed to non-filtered and non-concentrated ambient air containing PM_{2.5} for 24 h/day, 8 months (November 2012 to June 2013) using Taipei air pollution exposure system (TAPES), which was located at the inhalation toxicology laboratory of the Public Health building. Meanwhile, control group (n=5) were inhaled filtered air through a high-efficiency particulate air (HEPA) purifier added on the inlet valve of cage.

Rats were sacrificed by overdose Zoletil, and blood samples were collected from the abdominal aorta. The tissues including heart, liver, kidney, pancreas, spleen, testis and epididymis were taken and wrapped in aluminum foil, and snap-frozen with liquid nitrogen.

2.3 Lipid extraction

All the procedures of lipid extraction from different tissues and blood were



conducted by Chen et al. [55]. Briefly, the tissue samples were homogenized at a low temperature in liquid nitrogen, and freeze-dried for further lipid extraction. 1.0 mg tissue (or 0.01 mL serum) was spiked with the 1.0 mg/L internal standard including sphingomyelin (d18:1/17:0) in 0.2 mL of methanol. Next, the spiked sample was added 0.15 mL of 0.15 M sodium chloride_(aq) and 0.4 mL of chloroform after thorough vortexing. The mixtures were vortexed for 10 minutes and centrifuged at 10,000 rpm and 4 °C for 10 minutes. Eventually, 0.4 mL of the lower layer was collected and dried. The dried lipid extracts were reconstituted with 0.2 mL of methanol and filtered for further instrumental analysis.

2.4 UPLC-MS/MS for phosphorylcholine-containing lipids profiling

LC-MS method was based on our previous publication by Tang et al. [54] and the analysis was conducted by Chen et al. [55]. Three duplicate lipid samples from each tissue and serum of each rat were analyzed by Waters ACQUITY Ultra-performance liquid chromatography system coupled with Waters Quattro Premier XE triple quadrupole mass spectrometry (UPLC-MS/MS) (Waters, Milford, MA, USA).

Reversed-phase liquid chromatography with Waters BEH C₁₈ column (1.7 μm, 2.1 mm x 100 mm) was conducted in the binary solvent system, including A: 10 mM ammonium acetate in water and B: acetonitrile/methanol (65/35, v/v) containing 10 mM ammonium acetate. In MS system, the positive ion of the precursor ions of the mass-to-charge ratio (m/z) 184 was scanned, which was the signal of phosphorylcholine head

group in $[M+H]^+$ scan.



2.5 Data preprocessing

The raw MS spectra was transformed into NetCDF by Masslynx V4.1 software (Waters, CA, USA). Afterward MZmine 2.33. software [57] was applied to process and analyze mass spectrometry based molecular profile data. Briefly, we performed mass detection, chromatogram building, chromatogram deconvolution, deisotoping and alignment to develop a preliminary data list. The minimal signal intensity was 3000 and m/z tolerance was 1000 ppm. Next, we executed gap-filling check manually to filter out unstable signals and fill the correct integral areas. The m/z tolerance was 1000 ppm and RT tolerance was 0.1 min. Finally, the peak area of each detected lipid was normalized by the total spectra area using Excel (Office 2016, Microsoft, USA) to balance the variation of instrument sensitivity.

2.6 Multivariate analysis

The statistical analysis we used were divided into two methods, multivariate combine with univariate analysis. The processed data were imported into SIMCA 13.0.1 (Umetrics, Umeå, Sweden) for multivariate analysis. In SIMCA 13.0.1, after logarithm transformation and unit variance scaling, we performed partial least squares discriminant analysis (PLS-DA), a common supervised multivariate analysis which was applied in highly-dimensional dataset, such as metabolomics data [58]. The score plot of PLS-DA


model could visualize the clustering of samples, and the variable importance in projection (VIP) score indicated the contribution of each lipid for the difference between two groups.

The PLS-DA model was evaluated using R^2Y and Q^2 , which represent the model performance and prediction, respectively. The levels of R^2Y were higher than 0.9 indicated that the model was powerful; Q^2 values were not less than 0 indicated that the model was qualified [58]. In addition, permutation test, a statistical tool which rearranges the labels on the samples to calculate distribution of all possible statistic values, could confirm whether the model was over-fitting or not. We performed 500 randomly assigning samples to the two groups, and all of the 500 Q^2 levels in the randomly grouped models should be lower than the Q^2 in the original model or the intercept of random Q^2 regression line and Y axis should be below 0 [58].

2.7 Univariate analysis

The fold changes of identified lipid features were present by the median of peak area ratio between two groups. The univariate analysis was used to evaluate the statistical significance between two groups by independent variable. Owing to the sample size, Wilcoxon rank sum tests, the nonparametric statistics was conducted to examine the statistical significance between $PM_{2.5}$ treatment and control groups (p -value < 0.05) by R 3.3.1 project. Furthermore, false discovery rate (FDR) method was also used to compare two group strictly for avoiding false-positive findings caused by multiple testing (p -value < 0.2) [59]. In metabolomics, especially for detecting environmental impacts, often

tolerant FDR thresholds are used in order to capture as many features as possible, because environmental chemicals effects in the human metabolites may be slight [60]. However, only a few lipid features in the testis and serum were qualified FDR correction. Therefore, combining with multivariate analysis, we identified the significant changed lipid features that had p -values lower than 0.05 in Wilcoxon rank sum tests and VIP scores higher than 1.00 in the PLS-DA model.



3. Results



3.1 PM_{2.5} exposure data


The concentrations of PM_{2.5} in the exposure and control cages throughout the experiment were $16.7 \pm 10.1 \mu\text{g}/\text{m}^3$ and $0.70 \pm 0.46 \mu\text{g}/\text{m}^3$ (mean \pm standard deviation), respectively. PM_{2.5} is accounted for 99.2% of total PM less than 10 μm in diameter (PM₁₀) in the whole TAPES, which demonstrated the majority of the particles rats exposed to were PM_{2.5}. Furthermore, the major components of particles in TAPES were organic carbon (30.9%), sulfate (30.4%), ammonium (14.8%) and nitrate (11.4%), which showed typical traffic-related air pollution in Taipei City [55].

3.2 Phosphorylcholine-containing lipids composition in various organs of rat

After MS analysis and data preprocessing, the numbers of phosphorylcholine-containing lipid signals detected in each organ of rat were following: kidney was 128, pancreas was 126, testis was 123, spleen was 118, epididymis was 100, liver was 92, heart was 82, and lung from Chen et al. was 110 [55]. Furthermore, there were 68 lipid signals in serum of rat. Then, the lipid signals were identified by our in-house library with m/z and retention time. The numbers of lipids and percentages of each lipid class among total lipids in each organ and serum were shown in Figure 2.

The diacyl-PCs were the major lipid class, which almost accounted for half

percentage among total phosphorylcholine-containing lipids in all organs. SMs were second largest lipid class in each organ, and they were most abundant in the kidney than other organs. Besides, ether-linked PCs displayed slightly higher percentage in the epididymis (Figure 2).



3.3 Effects of PM_{2.5} on patterns of phosphorylcholine-containing lipids in the organs and serum of rats

In the PLS-DA model, each spot represents a sample, and the distance between two samples are closer which represents they are more similar. In this study, chronic ambient PM_{2.5} exposure mostly induced more phosphorylcholine-containing lipid changes in the testis, pancreas, and serum of rats, than those in the heart, liver and kidney of rats (Figure 3). No obvious changes on patterns of phosphorylcholine-containing lipids were found in the spleen and epididymis of rats after exposure.

In the testis, phosphorylcholine-containing lipids profile of the treatment group differed from that in the control group in PLS-DA model (Figure 3A). Besides, the total explained variance R²Y was 0.962 and the predictive ability Q² was 0.825. The PLS-DA model also satisfied the permutation test, because original Q² value was higher than randomized Q² values (Figure 4A).

In the pancreas, one sample in the exposure group of pancreas was excluded from following analysis as a result of its weak MS signal intensity which was approximately 10 times lower than other samples. We recorded this sample was not completely dried

after lyophilisation, which may cause PC degradation. In the PLS-DA model, phosphorylcholine-containing lipids profile of the pancreas in the treatment group also differed from that in the control group (Figure 3B). Besides, the total explained variance R^2Y was 0.972 and the predictive ability Q^2 was 0.833. The permutation test was also qualified (Figure 4B).


In the heart, the phosphorylcholine-containing lipids profile of the treatment group and control group presented a clear separation in PLS-DA model (Figure 3C). The total explained variance R^2Y was 0.933 and the predictive ability Q^2 was 0.627, and the model passed the permutation test absolutely (Figure 4C).

Liver samples have different phosphorylcholine-containing lipids pattern between treatment group and control group in PLS-DA model (Figure 3D). The acceptable total explained variance R^2Y and predictive ability Q^2 was 0.955 and 0.498, respectively. It also qualified permutation test result (Figure 4D).

In the PLS-DA model for the analysis of kidney, the pattern of treatment group seems to differ from that in the control group (Figure 3E), and the total explained variance R^2Y was 0.928, but the predictive ability Q^2 was 0.272. However, it was still considered that $PM_{2.5}$ exposure caused the significant alteration of phosphorylcholine-containing lipids in kidney of rat, due to its eligible permutation test result (Figure 4E).

Serum can reflect the systemic effect of exposure. The phosphorylcholine-containing lipids profile of $PM_{2.5}$ treatment group was quite different from that of control

group in PLS-DA model (Figure 3F). The total explained variance R^2Y was 0.977 and the predictive ability Q^2 was 0.885, and Figure 4F showed that the model satisfied the permutation test totally.



3.4 Effects of PM_{2.5} on individual phosphorylcholine-containing lipids in the organs and serum of rats

3.4.1 Testis

After Wilcoxon rank sum tests combined with the VIP scores of the PLS-DA model, 24 significantly changed testis phosphorylcholine-containing lipids were picked (Table 1). In the treatment group, the lyso-PCs including PC(16:1/0:0) + PC(0:0/16:1), PC(20:4/0:0), PC(0:0/18:1), PC(20:2/0:0) and PC(22:5/0:0), were significantly lower than those in control group. A few saturated and monounsaturated diacyl-PCs such as PC(16:0/16:0) and PC(16:0/18:1), and one ether-linked PC, PC(P-36:3), were also decreased in the rat testis after chronic PM_{2.5} treatment.

On the other hand, among nine changed diacyl-PCs, the levels of six polyunsaturated diacyl-PCs, including PC(18:2/20:4), PC(16:0/22:6), PC(34:4), PC(38:2), PC(42:6) and PC(42:4) had the same trend which is higher in the PM_{2.5} exposure group compared with those in the control group. Lastly, SMs such as SM(d18:2/23:0), SM(d18:2/16:0) and other unknown-SMs except SM(d34:1), were all higher than those in the control group. Noticeably, all the significantly changed phosphorylcholine-containing lipids of testis

passed the FDR correction (p -value < 0.2).



3.4.2 Pancreas

In the pancreas, five significantly changed phosphorylcholine-containing lipids were recognized after rats exposing to PM_{2.5} (Table 2). Comparing to that in the control group, the level of lyso-PC, PC(0:0/18:2) was higher in ambient PM_{2.5} treatment group. Besides, among four changed diacyl-PCs, three diacyl-PCs including PC(16:0/22:6), PC(18:0/22:6) and PC(44:4), were lower in treatment group than those in the control group. However, a diacyl-PC, PC(40:2), was increased after chronic PM_{2.5} treatment.

3.4.3 Other organs

In the heart and liver, only two phosphorylcholine-containing lipids satisfied both criteria of multivariate analysis (VIP score >1.00) and univariate analysis (p -value < 0.05) (Table 3), even though there were approximately 30 lipids with VIP scores higher than 1.00. The level of diacyl-PC(20:4/20:4) was increased, and the level of ether-linked PC, PC(O-18:0/16:0), was decreased in the heart of rat after chronic PM_{2.5} exposure (Table 3). In the liver, diacyl-PC(34:4) was 0.5-fold lower in treatment group than that in the control group (Table 3).

On the other hand, although four significantly changed phosphorylcholine-containing lipids were detected in the kidney, only an ether-linked PC, PC(O-18:0/16:0) was identified to decrease in the kidney of rat after chronic PM_{2.5} exposure (Table 3).

Interestingly, the increasing trend of unknown-SM was consistent with that in the testis.



3.4.4 Serum

After statistical analyses, seven significantly changed phosphorylcholine-containing lipids were recognized in the serum (Table 4), and four of them even passed the FDR correction (p -value < 0.2). The level of lyso-PC(18:0/0:0) was higher in the PM_{2.5} exposure group than that in the control group, moreover, unsaturated diacyl-PCs, including PC(16:0/16:1), PC(16:0/17:1), PC(16:0/18:1) and PC(16:0/20:4) were lower in the PM_{2.5} exposure group compared with those in the control group.

In addition, phosphorylcholine-containing lipids profiles in the serum were also used to find out the potential biomarkers for specific organs after PM_{2.5} exposure in the present study. After comparison of the changed lipids between serum and organs, decrease PC(16:0/18:1) was both found in the serum and testis in the PM_{2.5} treatment group compared with control group (Table 1 & 4).

4. Discussion



A previous literature has demonstrated that lung PC alterations of the rat that were exposed to ambient PM_{2.5} chronically, which were associated with inflammation, oxidative stress, and alveolar cell injuries [55]. However, The trend towards atypical respiratory-related disease was reported by epidemiological and toxicological studies on PM_{2.5} health effect [18]. Although there were few lipidomic studies about extrapulmonary effects of PM_{2.5} exposure, the perturbations of lipidome were found in the testis, pancreas, heart, liver and kidney of rat after chronic PM_{2.5} exposure in the present study. In this study, we applied an MS-based lipidomics approach to examine the changes in phosphorylcholine-containing lipids after rat inhalation of ambient air to further identify potential health effects of PM_{2.5}.

4.1 Lipidome comparison among various organs of rat


In this study, we established a foundational phosphorylcholine-containing lipid library of various rat organs through MS-based lipid profiling. This is the first study comparing phosphorylcholine-containing lipids in various organs. Our result showed that diacyl-PCs almost accounted for half percentage among total phosphorylcholine-containing lipids in all organs (Figure 2), and SMs account for 30% in the phosphorylcholine-containing lipids of rat kidney, which is most abundant among all organs (Figure 2A). Previous studies showed that SMs abound in phospholipid class

distribution of rat kidney comparing to other organs such as liver, spleen and heart [61-64]. Moreover, O-PC (alkyl ether bond) and P-PC (alkenyl ether bond), are richer in the rat epididymis than other organs (Figure 2E). In fact, spermatozoa from mammal animal such as human, ram and rat contain high levels of ether-linked PCs [65-68], and epididymis play a role in storage and maturation of spermatozoa [69, 70].

In addition, we also found that the lipid effects followed by chronic inhalation of PM_{2.5} particles. Our results suggested that testis was the most sensitive organ for PM_{2.5} through the results of PLS-DA model combined with Wilcoxon rank sum tests, which both present more significant alterations of lipidome than those in the other organs. Consequently, the potential mechanism underlying the rat sensitive organs after chronic PM_{2.5} exposure were discussed in the following sections.

4.2. Significantly changed phosphorylcholine-containing lipids in the rat testis after chronic PM_{2.5} treatment

In this study, we observed the significant decreased lyso-PCs, increased unsaturated diacyl-PCs, a decreased ether-linked PC and increased SMs in the testis of rat exposed to PM_{2.5}. The decreased levels of lyso-PCs and increased levels of unsaturated diacyl-PCs may be associated with membrane function. Lyso-PCs could influence the permeability and flexibility of membrane, due to their micelle property in lipid aggregated structures [71]. Thus, decreased lyso-PCs could be regarded as protective roles to promote membrane curvature to maintain stability [72], and to avoid forming the pores on




membrane [73]. In addition, the double bond on unsaturated fatty acyl chains of diacyl-PCs increases the inter-chain distance and forms space of membrane by creating the rigid kink in the hydrocarbon chain [74]. Comparing with the saturated diacyl-PCs, unsaturated diacyl-PCs can prevent fatty acyl chains from packing closely together and provide more fluidity and flexibility of membrane [74, 75]. Previous metabolomic study has also demonstrated increasing trends of unsaturated diacyl-PCs in testis of rats exposed to PM_{2.5}, the outcomes may affect sperm morphology and thus impaired the reproductive function of rats [76]. In this study, the decreased lyso-PCs and increased unsaturated diacyl-PCs in the testis may relate to promote the integrity of cell membrane.

On the other hand, most of up-regulation diacyl-PCs contained PUFA chains, including PC(18:2/20:4), PC(16:0/22:6), PC(34:4), PC(42:6) and PC(42:4). The increased unsaturated diacyl-PCs could not only bend membrane and enhance flexibility, but also supply capacity for surface area expansion and external force resistance, such as oxidative stress induced cell swelling [77, 78]. Therefore, increase diacyl-PCs contained PUFA chains may act as important roles to strengthen cellular function as well as resist further PM_{2.5}-induced oxidative stress.


In present study, we observed the decreased P-PC, PC(P-16:0/20:3), which may be associated with anti-oxidants. Ether-linked PCs are PCs with an ether bond at the sn-1 position which is more susceptible to oxidative attack than the ester-linked PCs [79, 80], however, they are also prone to autoxidation and thus inhibit peroxidation of PUFA [81].

Because the excessive oxidative stress may lead to cellular damage and aging, and even apoptosis [82, 83]. Therefore, the consumption of ether-linked PCs might play an anti-oxidant role to trigger self-protection mechanism, and protect other membrane constituents from oxidative conditions.



Five increased SMs were discovered in the testis after rat exposed to PM_{2.5} chronically. Although a few SMs with large molecular weight were unidentified due to shortage of database and insufficient MS signal intensity for structural identification, previous studies showed SMs indeed contain very long chain-fatty acid with at least 28 carbons in certain tissues such as testis and sperm [84, 85]. Through sphingomyelinases, hydrolysis of SMs generate simpler sphingolipids such as ceramides, which is involved in cell signaling events [86, 87], cell survival regulation and apoptosis [88, 89]. The accumulation of SMs may result from suppression of sphingomyelinase activity, importantly, SMs were demonstrated to serve as an endogenous anti-inflammatory molecule [90]. SMs helps maintain the integrity of the plasma membrane by protecting diacyl-PCs against phospholipase degradation. Previous study indicated that lecithin-cholesterol acyltransferase (LCAT) action is inhibited by SMs [91] and thereby regulate the eicosanoid synthesis and the inflammatory reactions [90, 92]. Thus, the increasing trend of testis SMs in this study may protect cell/tissue from PM_{2.5}-induced inflammation.


Furthermore, besides the general functions of phosphorylcholine-containing lipid species, the certain activities of those in the testis are also essential. Lyso-PCs, which



possessed a hydroxyl substituent at either the sn-1 or sn-2 position instead of the esterified linking fatty acyl substituent, can be converted back to PCs by the re-acylation of lysophosphatidylcholine acyltransferase (LPCAT) [93]. The perturbations in lyso-PCs could have resulted from abnormal enzyme activities [94], and previous study indicated overexpression of the LPCAT1 gene may contribute to the progression of human cancers [95], such as prostate cancer [96]. Thus, decreased lyso-PCs may correlate with some form of reproductive disease. In addition, dihydroxyacetonephosphate acyltransferase (DHAPAT) are enzymes involved in the synthesis of the ether bond on lipids in mammals, previous study described the DHAPAT-deficient mouse model with the lack of ether-linked lipids presented early arrest of spermatogenesis [97, 98]. It also be mention in the chapter 4.5. The SMs contain very long chain-fatty acid, particularly in testis, is related to maintain membrane integrity of spermatozoa, sperm capacitation and survive in the female reproductive tract [99, 100].

In conclusion of testis lipidome changes after PM_{2.5} exposure, the decreased lyso-PCs and increased unsaturated diacyl-PCs could strengthen the physical properties of cell membrane to resist membrane morphological alterations. Besides, the increased diacyl-PCs consisting of PUFAs and decreased ether-linked PCs were regarded as anti-oxidants, and increased SMs also act a protective role against inflammation induced by PM_{2.5}.

4.3 Contrary trend of changes of phosphorylcholine-containing lipid in the rat pancreas after chronic PM_{2.5} treatment




In this study, comparing to the results in the testis, we found the contrary trend of lipidome alterations such as an increased lyso-PC and decreased unsaturated diacyl-PCs in the pancreas after chronic PM_{2.5} treatment. The down-regulation of diacyl-PCs with unsaturated fatty acyl chains included PC(16:0/22:6), PC(18:0/22:6) and PC(44:4). Based on physical function of unsaturated diacyl-PCs on the cell membrane, it may be inferred a phenomenon of poor fluidity and flexibility of the membrane [74].

On the other hand, The position of double bonds on fatty acyl chains of diacyl-PCs is highly vulnerable to oxidative attack from free radicals, due to its much reactive attribute [101]. Under sustained attack, the diacyl-PCs become degraded through their fatty acid tails [102]. Thus, decreased unsaturated diacyl-PCs in the pancreas could result from damaged membrane integrity induced by elevating oxidative stress.

As we know, pancreas is an important organ about our blood glucose balance, and the pancreas dysfunction involves in each type of diabetes [103]. Besides, diabetes is one of the major risk factors for cardiovascular disease, and at least a half percent of people with diabetes die from some form of hypertension and cardiovascular disease [104]. Accordingly, the trend of changed lipids in the pancreas may be observed in the serum meanwhile.

Our results displayed only two increased lyso-PCs, PC(0:0/18:2) and PC(18:0/0:0),



after PM_{2.5} treatment, one is in the rat pancreas and the other in the serum. A lot of studies suggested the increased level of lyso-PCs in the plasma of diabetes mellitus and cardiovascular disease patients [105-108]. Lyso-PCs could be involved in the pathogenesis of type II diabetes by inducing insulin resistance and islet cell injury [109]. Martina Wallace et al. indicated that PC(0:0/18:2) and PC(18:0/0:0) are specific lipids highly associated with insulin resistance after lipidomic analysis on 39 human blood samples [110]. Besides, they also reported that, in the blood of human with insulin resistance, PC(34:1) and PC(36:4) have a negative association with CRP, which is a major marker of inflammation [110]. Interestingly, we also observed decreased diacyl-PCs, PC(16:0/18:1) and PC(16:0/20:4) in the serum after chronic PM_{2.5} treatment.

Additionally, the perturbations in lyso-PCs could have resulted from abnormal enzyme activities, lyso-PCs are produced by the cutting of PCs via the phospholipase A₂ (PLA₂) [111] or by the LCAT action on plasma lipoproteins [112]. Higher LCAT activity is correlated with insulin resistance and promotes metabolic syndrome [113]. Overproduction of lyso-PCs induced by enhanced activity of PLA₂ in endothelial cells [114], which lead to oxidative stress elevations as well as development of atherosclerosis [115, 116].

In conclusion of pancreas lipidome changes after PM_{2.5} exposure, the decreased unsaturated diacyl-PCs and increased lyso-PCs may indicate elevating oxidative stress and inflammation, which may associated with insulin resistance, early stage of diabetes

and cardiovascular disease.




4.4 Less changes of phosphorylcholine-containing lipids in other organs of rats after chronic PM_{2.5} treatment

Unlike the testis and pancreas, less changes of phosphorylcholine-containing lipids in the heart, liver, and kidney of rats exposed to PM_{2.5} chronically. It may attribute to the long-term and low-dose PM_{2.5} exposure, which provided the recovery period for slightly injury of those organs. Particularly in the liver, containing higher levels of glutathione which is an antioxidant to protect from PM_{2.5}-induced damages [117, 118]. However, it did not explain the totally changeless lipidome in the heart and kidney after chronic PM_{2.5} treatment, the PM_{2.5}-induced effects may reflect on the other classes of lipids.

4.5 Lipid alterations in blood may reflect to organ toxicity

The circulatory system is a network by circulating blood to transport molecular like nutrients, hormones, and metabolites to and from the different organs in the body. The alterations of phosphorylcholine-containing lipids in the rat serum after exposing to PM_{2.5} could reflect the PM_{2.5}-induced systemic effects from various organs by compare the results from serum with target organs, it may determine the potential exposure biomarkers of target organs for application in the future.

After chronic PM_{2.5} exposure, the overall alteration trend of subclass of phosphorylcholine-containing lipids in the serum was similar to those in the pancreas.



However, on the alteration of individual lipid, the consistent decreasing trend of a specific lipid, PC(16:0/18:1) (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC), was observed in the testis and serum after chronic PM_{2.5} treatment (Table 1 & 4). An imaging MS research indicated POPC located in the peripheral and the middle layer of the seminiferous tubules but not inner layer, which include spermatogonium and spermatocyte [119]. Based on the reduction of POPC, this result was consistent with our above inference about disturbance of early spermatogenesis [97, 98].

Remodeling of POPC is one of pathway to generate PC(16:0/16:0) (Dipalmitoylphosphatidylcholine, DPPC) which accounts for 60% in the pulmonary surfactant system [120, 121]. Previous study supported exogenous DPPC was able to protect a maintenance of spermatogenesis from chemotherapeutic agents-induced cytotoxicity, especially on morphological aspects [122]. Therefore, in the current study, the lower trend of testis DPPC attributed to insufficient POPC may cause dysfunction of spermatogenesis in PM_{2.5} treated rats. Besides, another study suggested palmitic acid (C16:0) and stearic acid (C18:0), substrates for POPC, could induce apoptosis in testicular Leydig cell [123], a type of interstitial cells is in charge of testosterone biosynthesis [124].

POPC was proved to serve as a component of the pulmonary surfactant system about alveolar surface tension in the past [120, 121], but the functions of POPC in the testis remain unclear now. Our previous study did not observe significantly changed POPC in the lung of rat from our identical PM_{2.5} treatment batch [55]. However, we revealed that

changes of POPC was simultaneously observed in the mouse lung and serum after naphthalene treatment [125, 126], which may relate to the PPAR α pathway in the pulmonary system [126]. Hence, PC(16:0/18:1) might be a unique and specific lipid in different organs under different environmental stimuli.


The alterations of blood lipids may be contributed from various organs, as a result, further studies to confirm whether PC(16:0/18:1) would be a potential biomarker of PM_{2.5} in the serum to measure testis effects are needed.

4.6 Limitation and future work

In this study, we focused on the phosphorylcholine-containing lipid effects after chronic PM_{2.5} exposure. However, the perturbations of other lipids are unknown. Additionally, in some organs such as pancreas, the levels of lipidome difference between two groups in PLS-DA model was not consistent with those in Wilcoxon rank sum tests; we speculate the univariate analysis was easily influenced by outlier sample, due to our small sample sizes (*n*). On the other hand, the lipid changes may occur in certain cell types of the organ; however, we are unable to confirm, due to an entire organ was used for analysis.

To our knowledge, this is the first study to examine the changes of phosphorylcholine-containing lipids in various organs and serum of rats after chronic exposure to low-dose PM_{2.5} by MS-based lipidomics. Although few researches demonstrated that the direct relation between PM_{2.5} and changes of lipids in


extrapulmonary organs, the underlying mechanisms is not clear. The results of this study provided the direction and foundation for future studies. In the future, further examination such as histopathological analysis focusing on the target organ—testis, and insulin resistance test on the pancreas will help us to clarify the potential important health effects of PM_{2.5} exposure on the male reproductive system and pancreas function.





References



1. Kampa, M. and E. Castanas, *Human health effects of air pollution*. Environ Pollut, 2008. 151(2): p. 362-7.
2. Yang, D., et al., *Ambient Air Pollution and Biomarkers of Health Effect*. Adv Exp Med Biol, 2017. 1017: p. 59-102.
3. Kim, K.-H., E. Kabir, and S. Kabir, *A review on the human health impact of airborne particulate matter*. Environment International, 2015. 74: p. 136-143.
4. Feng, S., et al., *The health effects of ambient PM_{2.5} and potential mechanisms*. Ecotoxicol Environ Saf, 2016. 128: p. 67-74.
5. Lin, Z.-Q., et al., *Oxidative Damage to Lung Tissue and Peripheral Blood in Endotracheal PM_{2.5}-treated Rats*. Biomedical and Environmental Sciences, 2009. 22(3): p. 223-228.
6. Wang, G., et al., *Rat lung response to ozone and fine particulate matter (PM_{2.5}) exposures*. 2015. 30(3): p. 343-356.
7. Sancini, G., et al., *Health Risk Assessment for Air Pollutants: Alterations in Lung and Cardiac Gene Expression in Mice Exposed to Milano Winter Fine Particulate Matter (PM_{2.5})*. PLOS ONE, 2014. 9(10): p. e109685.
8. Laden, F., et al., *Association of fine particulate matter from different sources with daily mortality in six US cities*. 2000. 108(10): p. 941-947.
9. Bell Michelle, L., et al., *Spatial and Temporal Variation in PM_{2.5} Chemical Composition in the United States for Health Effects Studies*. Environmental Health Perspectives, 2007. 115(7): p. 989-995.
10. Matawle, J.L., et al., *PM_{2.5} pollution from household solid fuel burning practices in central India: 1. Impact on indoor air quality and associated health risks*. 2017. 39(5): p. 1045-1058.
11. Löndahl, J., et al., *A set-up for field studies of respiratory tract deposition of fine and ultrafine particles in humans*. 2006. 37(9): p. 1152-1163.
12. Donaldson, K., et al., *Ambient particle inhalation and the cardiovascular system: potential mechanisms*. Environmental health perspectives, 2001. 109 Suppl 4(Suppl 4): p. 523-527.
13. Urmila P. Kodavanti, L.C.C., Daniel L. Costa, *Experimental Studies in Animals, in Cardiovascular Effects of Inhaled Ultrafine and Nanosized Particles*. 2011. p. 185-215.
14. Snow, S.J., et al., *Neuroendocrine Regulation of Air Pollution Health Effects: Emerging Insights*. Toxicological Sciences, 2018. 164(1): p. 9-20.
15. Halonen, J.I., et al., *Particulate air pollution and acute cardiorespiratory hospital admissions and mortality among the elderly*. 2009: p. 143-153.
16. Samoli, E., et al., *Acute effects of ambient particulate matter on mortality in Europe and North America: results from the APHENA study*. 2008. 116(11): p. 1480-1486.
17. Perez, L., et al., *Saharan dust, particulate matter and cause-specific mortality: A case-crossover study in Barcelona (Spain)*. Environment International, 2012. 48: p. 150-155.
18. Rückerl, R., et al., *Health effects of particulate air pollution: A review of epidemiological evidence*. Inhalation Toxicology, 2011. 23(10): p. 555-592.
19. Lafuente, R., et al., *Outdoor air pollution and sperm quality*. Fertility and Sterility, 2016. 106(4): p. 880-896.
20. Hammoud, A., et al., *Decreased sperm motility is associated with air pollution*


- 
- in Salt Lake City. *Fertility and Sterility*, 2010. 93(6): p. 1875-1879.
21. Zhou, N., et al., *Air pollution and decreased semen quality: A comparative study of Chongqing urban and rural areas*. *Environmental Pollution*, 2014. 187: p. 145-152.
 22. Wei, Y., et al., *Urban fine particulate matter (PM_{2.5}) exposure destroys blood-testis barrier (BTB) integrity through excessive ROS-mediated autophagy*. *Toxicol Mech Methods*, 2018. 28(4): p. 302-319.
 23. Yan, C., et al., *Long-term exposure to PM_{2.5} from automobile exhaust results in reproductive dysfunction in male rats*. *Zhonghua Nan Ke Xue*, 2016. 22(2): p. 104-9.
 24. Pearson, J.F., et al., *Association Between Fine Particulate Matter and Diabetes Prevalence in the U.S.* 2010. 33(10): p. 2196-2201.
 25. Sun, Q., et al., *Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity*. *Circulation*, 2009. 119(4): p. 538-546.
 26. Brook, R.D., et al., *Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association*. 2010. 121(21): p. 2331-2378.
 27. Weichenthal, S.A., K. Godri Pollitt, and P.J. Villeneuve, *PM_{2.5}, oxidant defence and cardiorespiratory health: a review*. *Environmental Health*, 2013. 12(1): p. 40.
 28. Ray, P.D., B.-W. Huang, and Y.J.C.s. Tsuji, *Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling*. 2012. 24(5): p. 981-990.
 29. Gehling, W., L. Khachatryan, and B. Dellinger, *Hydroxyl Radical Generation from Environmentally Persistent Free Radicals (EPFRs) in PM_{2.5}*. *Environmental Science & Technology*, 2014. 48(8): p. 4266-4272.
 30. Risom, L., P. Møller, and S. Loft, *Oxidative stress-induced DNA damage by particulate air pollution*. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, 2005. 592(1): p. 119-137.
 31. Schieber, M. and N.S. Chandel, *ROS function in redox signaling and oxidative stress*. *Current biology : CB*, 2014. 24(10): p. R453-R462.
 32. Li, R., et al., *Effect of ambient PM(2.5) on lung mitochondrial damage and fusion/fission gene expression in rats*. *Chem Res Toxicol*, 2015. 28(3): p. 408-18.
 33. Ribeiro, J.P., et al., *Toxicological effects of particulate matter (PM_{2.5}) on rats: Bioaccumulation, antioxidant alterations, lipid damage, and ABC transporter activity*. *Chemosphere*, 2016. 163: p. 569-577.
 34. Ulintz, L. and Q.J.E.D. Sun, *Ambient particulate matter pollution on lipid peroxidation in cardiovascular diseases*. 2016. 1(4): p. 109.
 35. Dowhan, W., M. Bogdanov, and E. Mileykovskaya, *CHAPTER 1 - Functional roles of lipids in membranes*, in *Biochemistry of Lipids, Lipoproteins and Membranes (Fifth Edition)*, D.E. Vance and J.E. Vance, Editors. 2008, Elsevier: San Diego. p. 1-37.
 36. Zhou, Q., et al., *Dispersion of atmospheric fine particulate matters in simulated lung fluid and their effects on model cell membranes*. *Science of The Total Environment*, 2016. 542: p. 36-43.
 37. Dai, J., et al., *Exposure to concentrated ambient fine particulate matter disrupts vascular endothelial cell barrier function via the IL-6/HIF-1alpha signaling pathway*. *FEBS Open Bio*, 2016. 6(7): p. 720-8.
 38. Chatterjee, S., *Chapter Two - Oxidative Stress, Inflammation, and Disease*, in

- 
- Oxidative Stress and Biomaterials*, T. Dziubla and D.A. Butterfield, Editors. 2016, Academic Press. p. 35-58.
39. Guan, L., et al., *PM2.5 exposure induces systemic inflammation and oxidative stress in an intracranial atherosclerosis rat model*. 2019. 34(4): p. 530-538.
 40. Niu, J., et al., *The Role of Metal Components in the Cardiovascular Effects of PM2.5*. PLOS ONE, 2013. 8(12): p. e83782.
 41. Zhao, J., et al., *The biological effects of individual-level PM2.5 exposure on systemic immunity and inflammatory response in traffic policemen*. 2013. 70(6): p. 426-431.
 42. Wang, G., et al., *Effects of ozone and fine particulate matter (PM2.5) on rat system inflammation and cardiac function*. Toxicology Letters, 2013. 217(1): p. 23-33.
 43. Chiurchiù, V., A. Leuti, and M. Maccarrone, *Bioactive Lipids and Chronic Inflammation: Managing the Fire Within*. Frontiers in immunology, 2018. 9: p. 38-38.
 44. Glass, C.K. and J.M. Olefsky, *Inflammation and lipid signaling in the etiology of insulin resistance*. Cell metabolism, 2012. 15(5): p. 635-645.
 45. Fahy, E., et al., *Update of the LIPID MAPS comprehensive classification system for lipids*. 2009. 50(Supplement): p. S9-S14.
 46. Zhao, Y.Y., et al., *Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease*. Chem Biol Interact, 2015. 240: p. 220-38.
 47. Loizides-Mangold, U., *On the future of mass-spectrometry-based lipidomics*. Febs j, 2013. 280(12): p. 2817-29.
 48. Wang, M., et al., *Novel advances in shotgun lipidomics for biology and medicine*. Prog Lipid Res, 2016. 61: p. 83-108.
 49. Zhao, C., et al., *Omics approach reveals metabolic disorders associated with the cytotoxicity of airborne particulate matter in human lung carcinoma cells*. Environmental Pollution, 2019. 246: p. 45-52.
 50. Xu, Y., et al., *Metabolomics analysis of a mouse model for chronic exposure to ambient PM2.5*. Environmental Pollution, 2019. 247: p. 953-963.
 51. Wang, X., et al., *Comprehensive pulmonary metabolome responses to intratracheal instillation of airborne fine particulate matter in rats*. Science of The Total Environment, 2017. 592: p. 41-50.
 52. van Meer, G., D.R. Voelker, and G.W. Feigenson, *Membrane lipids: where they are and how they behave*. Nature Reviews Molecular Cell Biology, 2008. 9: p. 112.
 53. Slotte, J.P., B.J.E.j.o.l.s. Ramstedt, and technology, *The functional role of sphingomyelin in cell membranes*. 2007. 109(10): p. 977-981.
 54. Tang, C.H., et al., *Glycerophosphocholine molecular species profiling in the biological tissue using UPLC/MS/MS*. J Chromatogr B Analyt Technol Biomed Life Sci, 2011. 879(22): p. 2095-106.
 55. Chen, W.L., et al., *Alterations in rat pulmonary phosphatidylcholines after chronic exposure to ambient fine particulate matter*. Mol Biosyst, 2014. 10(12): p. 3163-9.
 56. Yan, Y.H., et al., *Subchronic effects of inhaled ambient particulate matter on glucose homeostasis and target organ damage in a type 1 diabetic rat model*. Toxicol Appl Pharmacol, 2014. 281(2): p. 211-20.
 57. Pluskal, T., et al., *MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data*. BMC

- 
- Bioinformatics, 2010. 11: p. 395.
58. Worley, B. and R. Powers, *Multivariate Analysis in Metabolomics*. Current Metabolomics, 2013. 1(1): p. 92-107.
 59. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing*. 1995. 57(1): p. 289-300.
 60. Chong, E.Y., et al., *Local false discovery rate estimation using feature reliability in LC/MS metabolomics data*. Scientific Reports, 2015. 5: p. 17221.
 61. Yamanaka, W. and R.J.T.J.o.n. Ostwald, *Lipid composition of heart, kidney and lung in guinea pigs made anemic by dietary cholesterol*. 1968. 95(3): p. 381-387.
 62. Zambrano, F., et al., *Lipid composition of the Golgi apparatus of rat kidney and liver in comparison with other subcellular organelles*. 1975. 380(3): p. 357-369.
 63. Rouser, G., G. Simon, and G.J.L. Kritchevsky, *Species variations in phospholipid class distribution of organs: I. Kidney, liver and spleen*. 1969. 4(6): p. 599-606.
 64. Yamamoto, A., et al., *Studies on drug-induced lipidosis: VII. Effects of bis- β -diethylaminoethylether of hexestrol, chloroquine, homochlorocyclizine, prenylamine, and diazacholesterol on the lipid composition of rat liver and kidney*. 1976. 11(8): p. 616-622.
 65. Scott, T. and B.J.B.J. Setchell, *Lipid metabolism in the testis of the ram*. 1968. 107(2): p. 273-278.
 66. Scott, T.W. and R.M. Dawson, *Phospholipid interrelationships in rat epididymal tissue and spermatozoa*. The Biochemical journal, 1963. 87(3): p. 507-512.
 67. Leßig, J. and B. Fuchs, *Plasmalogens in Biological Systems: Their Role in Oxidative Processes in Biological Membranes, their Contribution to Pathological Processes and Aging and Plasmalogen Analysis*. Current Medicinal Chemistry, 2009. 16(16): p. 2021-2041.
 68. Selivonchick, D.P., et al., *Structure and metabolism of phospholipids in bovine epididymal spermatozoa*. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1980. 618(2): p. 242-254.
 69. Cornwall, G.A., *New insights into epididymal biology and function*. Human reproduction update, 2009. 15(2): p. 213-227.
 70. Prasad, M.R.N. and M. Rajalakshmi, *Comparative physiology of the mammalian epididymis*. General and Comparative Endocrinology, 1976. 28(4): p. 530-537.
 71. Hull, M.C., D.B. Sauer, and J.S. Hovis, *Influence of Lipid Chemistry on the Osmotic Response of Cell Membranes: Effect of Non-Bilayer Forming Lipids*. The Journal of Physical Chemistry B, 2004. 108(40): p. 15890-15895.
 72. Fuller, N. and R.P. Rand, *The Influence of Lysolipids on the Spontaneous Curvature and Bending Elasticity of Phospholipid Membranes*. Biophysical Journal, 2001. 81(1): p. 243-254.
 73. Tang, C.-H., et al., *Cellular membrane accommodation of copper-induced oxidative conditions in the coral Seriatopora caliendrum*. Aquatic Toxicology, 2014. 148: p. 1-8.
 74. Weijers, R.N.M., *Membrane flexibility, free fatty acids, and the onset of vascular and neurological lesions in type 2 diabetes*. Journal of diabetes and metabolic disorders, 2016. 15: p. 13-13.
 75. Murata, N. and D.A. Los, *Membrane Fluidity and Temperature Perception*. Plant physiology, 1997. 115(3): p. 875-879.
 76. Xiao-Fei, W., et al., *Study on Reproductive Toxicity of Fine Particulate Matter*

- 
- by *Metabolomics*. 2017. 45(5): p. 633-640.
77. Smith, H.L., et al., *Early Stages of Oxidative Stress-Induced Membrane Permeabilization: A Neutron Reflectometry Study*. Journal of the American Chemical Society, 2009. 131(10): p. 3631-3638.
 78. Shoemaker, S.D., T.K.J.I. Vanderlick, and e.c. research, *Stress-induced leakage from phospholipid vesicles: effect of membrane composition*. 2002. 41(3): p. 324-329.
 79. Mangold, H.K. and N.J.L. Weber, *Biosynthesis and biotransformation of ether lipids*. 1987. 22(11): p. 789-799.
 80. Broniec, A., et al., *Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems*. Free Radical Biology and Medicine, 2011. 50(7): p. 892-898.
 81. Sindelar, P.J., et al., *The protective role of plasmalogens in iron-induced lipid peroxidation*. Free Radical Biology and Medicine, 1999. 26(3): p. 318-324.
 82. Camhi, S.L., P. Lee, and A.M. Choi, *The oxidative stress response*. New horizons (Baltimore, Md.), 1995. 3(2): p. 170-182.
 83. Kannan, K. and S.K. Jain, *Oxidative stress and apoptosis*. Pathophysiology, 2000. 7(3): p. 153-163.
 84. Sandhoff, R., et al., *Novel Class of Glycosphingolipids Involved in Male Fertility*. 2005. 280(29): p. 27310-27318.
 85. Poulos, A., et al., *Occurrence of unusual molecular species of sphingomyelin containing 28-34-carbon polyenoic fatty acids in ram spermatozoa*. 1987. 248(3): p. 961-964.
 86. Adada, M., C. Luberto, and D. Canals, *Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases*. Chemistry and Physics of Lipids, 2016. 197: p. 45-59.
 87. Slotte, J.P., *Biological functions of sphingomyelins*. Progress in Lipid Research, 2013. 52(4): p. 424-437.
 88. Taniguchi, M. and T. Okazaki, *The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration—from cell and animal models to human disorders*. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014. 1841(5): p. 692-703.
 89. Teichgräber, V., et al., *Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis*. Nature Medicine, 2008. 14: p. 382.
 90. Subbaiah, P.V. and R.M. Sargis, *Sphingomyelin: a natural modulator of membrane homeostasis and inflammation*. Medical Hypotheses, 2001. 57(2): p. 135-138.
 91. Subbaiah, P.V. and M. Liu, *Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction*. 1993. 268(27): p. 20156-20163.
 92. Gesquiere, L., W. Cho, and P.V. Subbaiah, *Role of Group IIa and Group V Secretory Phospholipases A2 in the Metabolism of Lipoproteins. Substrate Specificities of the Enzymes and the Regulation of Their Activities by Sphingomyelin*. Biochemistry, 2002. 41(15): p. 4911-4920.
 93. Moessinger, C., et al., *Human Lysophosphatidylcholine Acyltransferases 1 and 2 Are Located in Lipid Droplets Where They Catalyze the Formation of Phosphatidylcholine*. 2011. 286(24): p. 21330-21339.
 94. Dong, J., et al., *Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers*. 2010. 6(4): p. 478-488.

- 
95. Law, S.-H., et al., *An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases*. 2019. 20(5): p. 1149.
96. Zhou, X., et al., *The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer*. *Experimental and Molecular Pathology*, 2012. 92(1): p. 105-110.
97. Rodemer, C., et al., *Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice*. *Human Molecular Genetics*, 2003. 12(15): p. 1881-1895.
98. Gorgas, K., et al., *The ether lipid-deficient mouse: Tracking down plasmalogen functions*. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 2006. 1763(12): p. 1511-1526.
99. Sandhoff, R., *Very long chain sphingolipids: Tissue expression, function and synthesis*. 2010. 584(9): p. 1907-1913.
100. Robinson, B.S., D.W. Johnson, and A. Poulos, *Novel molecular species of sphingomyelin containing 2-hydroxylated polyenoic very-long-chain fatty acids in mammalian testes and spermatozoa*. 1992. 267(3): p. 1746-51.
101. Ollila, S., M.T. Hyvönen, and I. Vattulainen, *Polyunsaturation in Lipid Membranes: Dynamic Properties and Lateral Pressure Profiles*. *The Journal of Physical Chemistry B*, 2007. 111(12): p. 3139-3150.
102. Kidd, P.M.J.A.M.R., *Phosphatidylcholine, a superior protectant against liver damage*. 1996. 1(4): p. 258-74.
103. Ann Pietrangelo, D.S., *The Connection Between Diabetes and Your Pancreas*, in *Healthline Media*. 2017.
104. Leon, B.M. and T.M. Maddox, *Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research*. *World journal of diabetes*, 2015. 6(13): p. 1246-1258.
105. Rabini, R.A., et al., *Reduced Na⁺-K⁺-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients*. 1994. 43(7): p. 915-919.
106. Stübiger, G., et al., *Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS*. 2012. 224(1): p. 177-186.
107. Sonoki, K., et al., *Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A₂, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus*. *Diabetes Research and Clinical Practice*, 2009. 86(2): p. 117-123.
108. Iwase, M., et al., *Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A₂ and effects of simvastatin treatment*. *Atherosclerosis*, 2008. 196(2): p. 931-936.
109. Han, M.S., et al., *Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance*. 2011. 52(6): p. 1234-1246.
110. Wallace, M., et al., *Relationship between the lipidome, inflammatory markers and insulin resistance*. 2014. 10(6): p. 1586-1595.
111. Baker, B.L., et al., *Quantification of the interaction between lysolecithin and phospholipase A₂*. *Biochim Biophys Acta*, 1994. 1211(3): p. 289-300.
112. Bhamidipati, S.P. and J.A. Hamilton, *Interactions of lyso 1-palmitoylphosphatidylcholine with phospholipids: a ¹³C and ³¹P NMR study*. *Biochemistry*, 1995. 34(16): p. 5666-77.

- 
113. Nass, K.J., et al., *Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease*. 2018. 48(9): p. e12988.
114. Packard, C.J., et al., *Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease*. 2000. 343(16): p. 1148-1155.
115. Kim, E.A., et al., *Lysophosphatidylcholine induces endothelial cell injury by nitric oxide production through oxidative stress*. 2009. 22(4): p. 325-331.
116. Schmitz, G. and K.J.A. Ruebsaamen, *Metabolism and atherogenic disease association of lysophosphatidylcholine*. 2010. 208(1): p. 10-18.
117. Rajendra Sharma, Y.Y., Abha Sharma, Sanjay Awasthi, and Yogesh C. Awasthi, *Antioxidant Role of Glutathione S-Transferases: Protection Against Oxidant Toxicity and Regulation of Stress-Mediated Apoptosis*. 2004. 6(2): p. 289-300.
118. Saxon, A. and D. Diaz-Sanchez, *Air pollution and allergy: you are what you breathe*. *Nature Immunology*, 2005. 6(3): p. 223-226.
119. Goto-Inoue, N., et al., *Imaging mass spectrometry reveals changes of metabolites distribution in mouse testis during testicular maturation*. 2012. 44(6): p. 749-754.
120. Dushianthan, A., et al., *Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome - where do we go from here?* *Critical Care*, 2012. 16(6): p. 238.
121. Agassandian, M. and R.K. Mallampalli, *Surfactant phospholipid metabolism*. *Biochimica et biophysica acta*, 2013. 1831(3): p. 612-625.
122. Favareto, A.P.A., et al., *Evaluation of testicular tissue of adult rats treated with cisplatin incorporated into the liposome*. 2015. 78(4): p. 323-329.
123. Lu, Z.-H., et al., *Saturated free fatty acids, palmitic acid and stearic acid, induce apoptosis by stimulation of ceramide generation in rat testicular Leydig cell*. *Biochemical and Biophysical Research Communications*, 2003. 303(4): p. 1002-1007.
124. Pelosi, E. and P. Koopman, *Development of the Testis*, in *Reference Module in Biomedical Sciences*. 2017, Elsevier.
125. Lee, S.-H., et al., *Mass spectrometry-based lipidomics to explore the biochemical effects of naphthalene toxicity or tolerance in a mouse model*. *PLOS ONE*, 2018. 13(10): p. e0204829.
126. Chen, K.-H., *Mass Spectrometry-Based Lipidomics to Study Early Event of Naphthalene Toxicity in Mice*, in *Institute of Environmental health*. 2015, National Taiwan University. p. 1-86.



Figures

Phosphorylcholine-containing lipids

Representative structures




Figure 1. Representative structures of various phosphorylcholine-containing lipids.




Figure 2. Phosphorylcholine-containing lipids composition in each organ of rat. (A) Kidney (B) Pancreas (C) Testis (D) Spleen (E) Lung (F) Epididymis (G) Liver (H) Heart (I) Serum. ^a Number of identified lipids for each lipid subclass; ^b Percentage of identified lipids for each lipid subclass.

Lyso-PCs: lyso-phosphatidylcholines; Diacyl-PCs: diacyl-phosphatidylcholines; O-PCs: O-alkyl-acyl-PC (plasmanylcholines); P-PCs: O-alkenyl-acyl-PC (plasmenylcholines); Unknown-PCs: unknown-phosphatidylcholines; SMs: sphingomyelins.




Figure 3. The PLS-DA score plots from the analysis of UPLC-MS/MS spectra of phosphorylcholine-containing lipids in each organ of rats after chronic ambient PM_{2.5} exposure. (A) Testis, R²Y: 0.962, Q²: 0.825 (B) Pancreas, R²Y: 0.972, Q²: 0.833 (C) Heart, R²Y: 0.933, Q²: 0.627 (D) Liver, R²Y: 0.955, Q²: 0.498 (E) Kidney, R²Y: 0.928, Q²: 0.272 (F) Serum, R²Y: 0.977, Q²: 0.885. Rad circle: exposure PM_{2.5} group; Green square: control group.




Figure 4. Permutation test of PLS-DA model for phosphorylcholine-containing lipids in each organ of rats after chronic ambient PM_{2.5} exposure. (A) Testis (B) Pancreas (C) Heart (D) Liver (E) Kidney (F) Serum. 500 times permutation tests were used in the study. All groups accorded with the requirement of the standard. R² presented on green circles and Q² presented on blue boxes.



Tables

Table 1. Significant changed phosphorylcholine-containing lipids in the testis of rats after chronic ambient PM_{2.5} exposure.

Subclass	Lipid name	VIP ^a	Fold change ^b	Wilcoxon rank sum tests (<i>p</i> -value) ^c	
Lyso-PCs	PC(16:1/0:0) + PC(0:0/16:1)	1.62	0.12	*	
	PC(20:4/0:0)	1.94	0.04	**	
	PC(0:0/18:1)	1.91	0.06	**	
	PC(20:2/0:0)	1.59	0.08	**	
	PC(22:5/0:0)	1.89	0.03	**	
Saturated	PC(16:0/16:0)	1.76	0.72	**	
	Monounsaturated	PC(16:0/18:1)	1.54	0.95	*
Diacyl-PCs	PC(22:5/18:0)	1.66	0.55	*	
	PC(18:2/20:4)	1.63	2.58	*	
	PC(16:0/22:6)	1.11	1.45	*	
	Polyunsaturated	PC(34:4)	1.32	1.54	*
		PC(38:2)	1.39	1.58	*
		PC(42:6)	1.52	2.09	**
		PC(42:4)	1.34	1.43	*

^a Variable Importance Projection of PLS-DA component 1; ^b Fold change calculated by the median peak area ratio of treatment group and control group; ^c All the features were qualified false discovery rate correction. * *p*-value < 0.05; ** *p*-value < 0.01.

Lyso-PCs: lyso-phosphatidylcholines; Diacyl-PCs: diacyl-phosphatidylcholines.

Table 1. Significant changed phosphorylcholine-containing lipids in the testis of rats after chronic ambient PM_{2.5} exposure. (continued)

Subclass	Lipid name	VIP ^a	Fold change ^b	Wilcoxon rank sum tests (<i>p</i> -value) ^c
P-PCs	PC(P-16:0/20:3)	1.69	0.66	*
Sphingomyelins	SM(d18:2/23:0)	1.37	2.01	*
	SM(d18:2/16:0)	1.49	2.18	*
	SM(d34:1)	1.29	0.42	*
Unknown	PC(509)	2.03	0.68	**
	PC(597)	1.99	0.05	**
	PC(599)	1.78	0.08	**
	SM(862)	1.95	1.88	**
	SM(878)	1.82	1.84	*
	SM(888)	1.72	2.33	*

^a Variable Importance Projection of PLS-DA component 1; ^b Fold change calculated by the median peak area ratio of treatment group and control group; ^c All the features qualified false discovery rate correction. * *p*-value < 0.05; ** *p*-value < 0.01. P-PCs: O-alkenyl-acyl-PC (plasmeylcholines).

Table 2. Significant changed phosphorylcholine-containing lipids in the pancreas of rats after chronic ambient PM_{2.5} exposure.

Subclass	Lipid name	VIP ^a	Fold change ^b	Wilcoxon rank sum tests (<i>p</i> -value)
Lyso-PCs	PC(0:0/18:2)	2.49	1.55	*
	PC(40:2)	1.32	1.24	*
Diacyl-PCs	PC(16:0/22:6)	2.50	0.67	*
	PC(18:0/22:6)	2.62	0.74	*
	PC(44:4)	1.99	0.46	*

^a Variable Importance Projection of PLS-DA component 1; ^b Fold change calculated by the median peak area ratio of treatment group and control group. * *p*-value < 0.05; ** *p*-value < 0.01. Lyso-PCs: lyso-phosphatidylcholines; Diacyl-PCs: diacyl-phosphatidylcholines.

Table 3. Significant changed phosphorylcholine-containing lipids in the heart, liver, and kidney of rats after chronic ambient PM_{2.5} exposure.

Organs	Subclass	Lipid name	VIP ^a	Fold change ^b	Wilcoxon rank sum tests (<i>p</i> -value)
Heart	Polyunsaturated diacyl-PCs	PC(20:4/20:4)	2.83	1.23	*
	O-PCs	PC(O-18:0/16:0)	1.96	0.75	*
Liver	Polyunsaturated diacyl-PCs	PC(34:4)	2.50	0.53	*
	Unknown	PC(827)	1.31	0.77	*
Kidney	O-PCs	PC(O-18:0/16:0)	1.66	0.64	*
	Unknown	PC(843)	1.81	0.80	*
		PC(863)	1.04	0.78	*
		SM(872)	2.69	1.46	*

^a Variable Importance Projection of PLS-DA component 1; ^b Fold change calculated by the median peak area ratio of treatment group and control group. * *p*-value < 0.05; ** *p*-value < 0.01. Diacyl-PCs: diacyl-phosphatidylcholines; O-PC: O-alkyl-acyl-PCs (Plasmanycholines).

Table 4. Significant changed phosphorylcholine-containing lipids in the serum of rats after chronic ambient PM_{2.5} exposure.

Subclass	Lipid name	VIP ^a	Fold change ^b	Wilcoxon rank sum tests (<i>p</i> -value)	
Lyso-PCs	PC(18:0/0:0)	2.30	1.34	** ^c	
Diacyl-PCs	Monounsaturated	PC(16:0/16:1)	2.19	0.60	** ^c
		PC(16:0/17:1)	1.52	0.74	*
	Polyunsaturated	PC(16:0/18:1)	1.69	0.83	*
		PC(16:0/20:4)	2.31	0.83	** ^c
		PC(22:5/20:3)	1.52	1.30	** ^c
Unknown	PC(843)	1.37	1.25	*	

^a Variable Importance Projection of PLS-DA component 1; ^b Fold change calculated by the median peak area ratio of treatment group and control group; ^c Qualified false discovery rate correction. * *p*-value < 0.05; ** *p*-value < 0.01. Lyso-PCs: lyso-phosphatidylcholines; Diacyl-PCs: diacyl-phosphatidylcholines.